Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement

Sponsor
Smith & Nephew, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT03250767
Collaborator
(none)
140
8
140
17.5
0.1

Study Details

Study Description

Brief Summary

A post market, prospective, non-randomized, multi-center, open-label, clinical study using survivorship as the reference performance goal to study the safety and efficacy of the Titan Modular Shoulder System 2.5 when used for primary shoulder arthroplasty.

Condition or Disease Intervention/Treatment Phase
  • Device: Integra Titan Modular Shoulder System 2.5

Study Design

Study Type:
Observational
Anticipated Enrollment :
140 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement
Actual Study Start Date :
Aug 1, 2017
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Apr 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Integra Titan Modular Shoulder System 2.5

Device: Integra Titan Modular Shoulder System 2.5
Primary Shoulder Joint Replacement

Outcome Measures

Primary Outcome Measures

  1. Implant Survivorship [2 years]

    Implant survivorship defined as absence of device removal or revision

Secondary Outcome Measures

  1. Implant Survivorship [1,5 and 10 years]

    Implant survivorship defined as absence of device removal or revision

  2. Relative change of Range of Motion (ROM) compared to baseline [up to 10 years]

    Relative change of ROM compared to baseline

  3. Relative change of Constant-Murley Score (CMS) compared to baseline [up to 10 years]

    Relative change of CMS compared to baseline

  4. Relative change of American Shoulder & Elbow Surgeons Score (ASES) compared to baseline [up to 10 years]

    Relative change of ASES compared to baseline

  5. Relative change of Single Assessment Numeric Evaluation (SANE) compared to baseline [up to 10 years]

    Relative change of SANE compared to baseline

  6. Relative change of Simple Shoulder Test (SST) compared to baseline [up to 10 years]

    Relative change of SST compared to baseline

  7. Relative change of Pain compared to baseline [up to 10 years]

    Relative change of Visual Analogue Scale (VAS) Pain compared to baseline

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • For total shoulder arthroplasty, subjects must meet a, b, or c below:
  1. Severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis

  2. Fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicates that alternative methods of treatment are unsatisfactory

  3. Other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. -revision of a failed primary component)

  • For shoulder hemiarthroplasty, subjects must meet any of the sub-criteria a - g below:
  1. Severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis

  2. Fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicates that alternative methods of treatment are unsatisfactory

  3. Other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. -revision of a failed primary component)

  4. Ununited humeral head fractures

  5. Avascular necrosis of the humeral head

  6. Rotator cuff arthropathy

  7. Deformity and/or limited motion

Exclusion Criteria:
  • Absent, irreparable or nonfunctional rotator cuff or other essential muscles.

  • Have an active local or systemic infection.

  • Have inadequate bone stock in the proximal humerus or glenoid fossa for supporting the components.

  • Have poor bone quality such as osteoporosis where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.

  • Have a muscular, neurologic, or vascular deficiencies that compromise the affected extremity.

  • Have a known sensitivity or allergic reaction to one or more of the implanted materials.

  • Have a condition that may impair proper wound healing.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Alabama at Birmingham Birmingham Alabama United States 35294-0111
2 John Hopkins University Columbia Maryland United States 21044
3 Mississipi Bone and Joint Clinic Starkville Mississippi United States 39759
4 The Research Foundation for The State University of New York (SUNY) Syracuse New York United States 13210
5 Westphal Orthopaedics Lancaster Pennsylvania United States 17601
6 Hospital of the University of Pennsylvania Philadelphia Pennsylvania United States 19104
7 The Rothman Institute Philadelphia Pennsylvania United States 19107
8 University of Virginia Health System Charlottesville Virginia United States 22911

Sponsors and Collaborators

  • Smith & Nephew, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Smith & Nephew, Inc.
ClinicalTrials.gov Identifier:
NCT03250767
Other Study ID Numbers:
  • T-TSS-003
First Posted:
Aug 16, 2017
Last Update Posted:
Feb 9, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2022